Ardelyx Inc

ARDX

Equity

ISIN US0396971071 / Valor 24511822

NASDAQ (2024-11-22)

USD 5.31+3.71%

Ardelyx Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Ardelyx Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative, minimally-systemic therapeutics for the treatment of renal and cardiovascular diseases.

Summarized from source with an LLMView SourceSector: Technology

Q1 2024 Total Revenue

Ardelyx Inc. reported a significant increase in total revenue for the first quarter of 2024, amounting to $46.0 million. This is a substantial rise from the $11.4 million recorded in the same quarter of the previous year, primarily driven by increased net product sales and product supply revenue.

Q1 2024 Net Loss

For the first quarter of 2024, Ardelyx Inc. recorded a net loss of $26.5 million, or $(0.11) per share. This represents a slight improvement compared to the net loss of $26.8 million, or $(0.13) per share, reported in the first quarter of 2023.

Q1 2024 SG&A Expenses

Ardelyx Inc.'s selling, general, and administrative expenses for the first quarter of 2024 were $53.0 million. This marks an increase of $26.2 million from the $26.8 million reported in the first quarter of the previous year, reflecting the company's expanded commercial activities.

Q1 2024 Cash Position

As of March 31, 2024, Ardelyx Inc. reported a strong cash position with total cash, cash equivalents, and short-term investments of $202.6 million. This is an increase from $184.3 million as of December 31, 2023, supporting the company's operational and development activities.

Q1 2024 Product Sales

During the first quarter of 2024, Ardelyx Inc. achieved $28.4 million in net product sales revenue from IBSRELA and $15.2 million from XPHOZAH. These figures demonstrate significant growth in product sales, contributing to the overall increase in the company's revenue for the quarter.

Summarized from source with an LLMView Source

Key figures

23.2%1Y

470%3Y

-17.3%5Y

Performance

78.6%1Y

88.4%3Y

100%5Y

Volatility